Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.570
-0.120 (-2.56%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Myriad Genetics Revenue
Myriad Genetics had revenue of $200.40M in the quarter ending March 31, 2026, with 2.30% growth. This brings the company's revenue in the last twelve months to $829.00M, down -0.28% year-over-year. In the year 2025, Myriad Genetics had annual revenue of $824.50M, down -1.56%.
Revenue (ttm)
$829.00M
Revenue Growth
-0.28%
P/S Ratio
0.52
Revenue / Employee
$307,037
Employees
2,700
Market Cap
431.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 824.50M | -13.10M | -1.56% |
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.50M | 23.96% |
| Dec 31, 2020 | 557.10M | -81.50M | -12.76% |
| Jun 30, 2020 | 638.60M | -212.50M | -24.97% |
| Jun 30, 2019 | 851.10M | 107.40M | 14.44% |
| Jun 30, 2018 | 743.70M | 15.00M | 2.06% |
| Jun 30, 2017 | 728.70M | -11.80M | -1.59% |
| Jun 30, 2016 | 740.50M | 17.40M | 2.41% |
| Jun 30, 2015 | 723.10M | -55.10M | -7.08% |
| Jun 30, 2014 | 778.20M | 165.00M | 26.91% |
| Jun 30, 2013 | 613.20M | 117.20M | 23.63% |
| Jun 30, 2012 | 496.01M | 93.92M | 23.36% |
| Jun 30, 2011 | 402.08M | 39.44M | 10.87% |
| Jun 30, 2010 | 362.65M | 36.12M | 11.06% |
| Jun 30, 2009 | 326.53M | 103.67M | 46.52% |
| Jun 30, 2008 | 222.86M | 77.57M | 53.39% |
| Jun 30, 2007 | 145.29M | 31.01M | 27.13% |
| Jun 30, 2006 | 114.28M | 31.87M | 38.68% |
| Jun 30, 2005 | 82.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| Biodesix | 96.10M |
| Prenetics Global | 92.39M |
MYGN News
- 2 days ago - Myriad Genetics Transcript: AGM 2026 - Transcripts
- 4 days ago - Myriad Genetics appoints Raj Jampa as chief technology officer - TheFly
- 4 days ago - Myriad Genetics Names Raj Jampa as New Chief Technology Officer - GlobeNewsWire
- 10 days ago - Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting - GlobeNewsWire
- 10 days ago - Myriad Genetics launches Prolaris + AI - TheFly
- 11 days ago - Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) - GlobeNewsWire
- 22 days ago - Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life - GlobeNewsWire
- 4 weeks ago - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - GlobeNewsWire